Literature DB >> 12949147

Inferring evolutionary rates using serially sampled sequences from several populations.

Allen G Rodrigo1, Matthew Goode, Roald Forsberg, Howard A Ross, Alexei Drummond.   

Abstract

The estimation of evolutionary rates from serially sampled sequences has recently been the focus of several studies. In this paper, we extend these analyzes to allow the estimation of a joint rate of substitution, omega, from several evolving populations from which serial samples are drawn. In the case of viruses evolving in different hosts, therapy may halt replication and therefore the accumulation of substitutions in the population. In such cases, it may be that only a proportion, p, of subjects are nonresponders who have viral populations that continue to evolve. We develop two likelihood-based procedures to jointly estimate p and omega, and empirical Bayes' tests of whether an individual should be classified as a responder or nonresponder. An example data set comprising HIV-1 partial envelope sequences from six patients on highly active antiretroviral therapy is analyzed.

Entities:  

Mesh:

Year:  2003        PMID: 12949147     DOI: 10.1093/molbev/msg215

Source DB:  PubMed          Journal:  Mol Biol Evol        ISSN: 0737-4038            Impact factor:   16.240


  9 in total

1.  Impact of CCR5delta32 host genetic background and disease progression on HIV-1 intrahost evolutionary processes: efficient hypothesis testing through hierarchical phylogenetic models.

Authors:  Diana Edo-Matas; Philippe Lemey; Jennifer A Tom; Cèlia Serna-Bolea; Agnes E van den Blink; Angélique B van 't Wout; Hanneke Schuitemaker; Marc A Suchard
Journal:  Mol Biol Evol       Date:  2010-12-06       Impact factor: 16.240

2.  Test of genetical isochronism for longitudinal samples of DNA sequences.

Authors:  Xiaoming Liu; Yun-Xin Fu
Journal:  Genetics       Date:  2007-02-04       Impact factor: 4.562

3.  Summary statistics of neutral mutations in longitudinal DNA samples.

Authors:  Xiaoming Liu; Yun-Xin Fu
Journal:  Theor Popul Biol       Date:  2008-05-05       Impact factor: 1.570

4.  The evolutionary rate dynamically tracks changes in HIV-1 epidemics: application of a simple method for optimizing the evolutionary rate in phylogenetic trees with longitudinal data.

Authors:  Irina Maljkovic Berry; Gayathri Athreya; Moulik Kothari; Marcus Daniels; William J Bruno; Bette Korber; Carla Kuiken; Ruy M Ribeiro; Thomas Leitner
Journal:  Epidemics       Date:  2009-11-12       Impact factor: 4.396

5.  Clinical implications of evolutionary patterns of homologous, full-length hepatitis B virus quasispecies in different hosts after perinatal infection.

Authors:  Feng Liu; De-Min Yu; Su-Yuan Huang; Jia-Lun Yu; Dong-Hua Zhang; Qi-Ming Gong; Xin-Xin Zhang
Journal:  J Clin Microbiol       Date:  2014-02-26       Impact factor: 5.948

6.  Unequal evolutionary rates in the human immunodeficiency virus type 1 (HIV-1) pandemic: the evolutionary rate of HIV-1 slows down when the epidemic rate increases.

Authors:  Irina Maljkovic Berry; Ruy Ribeiro; Moulik Kothari; Gayathri Athreya; Marcus Daniels; Ha Youn Lee; William Bruno; Thomas Leitner
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

7.  Genomic analysis of hepatitis B virus reveals antigen state and genotype as sources of evolutionary rate variation.

Authors:  Abby Harrison; Philippe Lemey; Matthew Hurles; Chris Moyes; Susanne Horn; Jan Pryor; Joji Malani; Mathias Supuri; Andrew Masta; Burentau Teriboriki; Tebuka Toatu; David Penny; Andrew Rambaut; Beth Shapiro
Journal:  Viruses       Date:  2011-02       Impact factor: 5.048

8.  Repertoire-wide phylogenetic models of B cell molecular evolution reveal evolutionary signatures of aging and vaccination.

Authors:  Kenneth B Hoehn; Jason A Vander Heiden; Julian Q Zhou; Gerton Lunter; Oliver G Pybus; Steven H Kleinstein
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-21       Impact factor: 11.205

9.  A framework including recombination for analyzing the dynamics of within-host HIV genetic diversity.

Authors:  Ori Sargsyan
Journal:  PLoS One       Date:  2014-02-07       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.